Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.49 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 4/20 | 0.48 |
| ▸ | CA1 | P00915 | 4/20 | 0.48 |
| ▸ | CA2 | P00918 | 4/20 | 0.48 |
| ▸ | CA7 | P43166 | 4/20 | 0.48 |
| ▸ | CA9 | Q16790 | 4/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30784110 | 1.00 | NPC1 (0.54) | NPC1TSHRHTTPDCD1CD274 | |
| SCHEMBL1785248 | 0.89 | TSHR (0.52) | NPC1TSHRHTTALDH1A1KDM4E | |
| SCHEMBL137907 | 0.86 | NPC1 (0.62) | NPC1TSHRHTTPDCD1CD274 | |
| SCHEMBL5841557 | 0.84 | NPC1 (0.50) | NPC1TSHRHTTPDCD1CD274 | |
| SCHEMBL1785225 | 0.84 | TSHR (0.59) | NPC1TSHRHTTALDH1A1KDM4E | |
| SCHEMBL7593464 | 0.84 | CA12 (0.58) | NPC1TSHRHTTPDCD1CD274 | |
| SCHEMBL31454731 | 0.84 | TSHR (0.59) | NPC1TSHRHTTALDH1A1KDM4E | |
| SCHEMBL4833869 | 0.84 | TSHR (0.49) | NPC1TSHRHTTALDH1A1KDM4E | |
| SCHEMBL17707767 | 0.82 | NPC1 (0.49) | NPC1TSHRHTTPDCD1CD274 | |
| SCHEMBL22164112 | 0.80 | NPC1 (0.57) | NPC1TSHRHTTPDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024026424-A1 | QUINAZOLINONE DERIVATIVES AS AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20200147597-A1 | HYDROGENATION AND DEHYDROGENATION CATALYST, AND METHODS OF MAKING AND USING THE SAME | GOUSSEV DMITRI (CA) | 2020-05-14 | — | — | US | disclosed |
| EP-2744815-B1 | HYDROGENATION AND DEHYDROGENATION CATALYST, AND METHODS OF MAKING AND USING THE SAME | GOUSSEV DMITRI (CA) | 2019-01-16 | — | — | EP | disclosed |
| CN-104496899-A | Synthesis method of midbody of Montelukast sodium | ARROMAX PHARMACEUTICAL TECHNOLOGY SUZHOU CO LTD | 2015-04-08 | — | — | CN | disclosed |
| US-20140328748-A1 | HYDROGENATION AND DEHYDROGENATION CATALYST, AND METHODS OF MAKING AND USING THE SAME | GOUSSEV DMITRI (CA) | 2014-11-06 | — | — | US | disclosed |
| US-20140328748-A1 | HYDROGENATION AND DEHYDROGENATION CATALYST, AND METHODS OF MAKING AND USING THE SAME | GOUSSEV DMITRI (CA) | 2014-11-06 | — | — | US | disclosed |
| WO-2013023307-A1 | HYDROGENATION AND DEHYDROGENATION CATALYST, AND METHODS OF MAKING AND USING THE SAME | GOUSSEV DMITRI (CA) | 2013-02-21 | — | — | WO | disclosed |
| US-20120190861-A1 | Levodopa Prodrugs, and Compositions and Uses Thereof | XENOPORT, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| EP-1751087-B1 | LEVODOPA DERIVATIVES, AND COMPOSITIONS AND USES THEREOF | XENOPORT INC (US) | 2012-06-27 | — | — | EP | disclosed |
| US-8163958-B2 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-7534813-B2 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-20080132570-A1 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-7342131-B2 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2008-03-11 | — | — | US | disclosed |
| US-20050282891-A1 | Levodopa prodrugs, and compositions and uses thereof | WILSHIRE PHARMACEUTICALS, INC. | 2005-12-22 | — | — | US | disclosed |
| EP-0461079-B1 | Substituted phthalides and heterocyclic phthalides | CIBA GEIGY AG (CH) | 1997-07-16 | — | — | EP | disclosed |
| US-5627138-A | HERBICIDES | SANDOZ LTD. (CH) | 1997-05-06 | — | — | US | disclosed |
| US-5627137-A | HERBICIDES | SANDOZ LTD. (CH) | 1997-05-06 | — | — | US | disclosed |
| US-5561101-A | HERBICIDES | SANDOZ LTD. (CH) | 1996-10-01 | — | — | US | disclosed |
| US-5506192-A | HERBICIDES | SANDOZ LTD. | 1996-04-09 | — | — | US | disclosed |
| EP-0461079-A2 | Substituted phthalides and heterocyclic phthalides | SANDOZ LTD. (CH) | 1991-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200147597-A1 | HYDROGENATION AND DEHYDROGENATION CATALYST, AND METHODS OF MAKING AND USING THE SAME | HSDL2, HSD11B2, HSD11B1 | NPC1 3647/4885TSHR 2469/4885HTT 1248/4885 |
| US-20080132570-A1 | Levodopa prodrugs, and compositions and uses thereof | COMT, DDT, DDC | NPC1 3417/4885TSHR 2158/4885HTT 648/4885 |
| US-20140328748-A1 | HYDROGENATION AND DEHYDROGENATION CATALYST, AND METHODS OF MAKING AND USING THE SAME | HSDL2, HSD11B2, HSD11B1 | NPC1 3647/4885TSHR 2469/4885HTT 1248/4885 |
| US-20050282891-A1 | Levodopa prodrugs, and compositions and uses thereof | COMT, DDT, DDC | NPC1 3417/4885TSHR 2158/4885HTT 648/4885 |
| US-20120190861-A1 | Levodopa Prodrugs, and Compositions and Uses Thereof | COMT, DDT, DDC | NPC1 3417/4885TSHR 2158/4885HTT 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.